206 related articles for article (PubMed ID: 20131968)
21. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
Bruno F; Baratti D; Martinetti A; Morelli D; Sottotetti E; Bonini C; Guaglio M; Kusamura S; Deraco M
Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128
[TBL] [Abstract][Full Text] [Related]
22. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
De Santi C; Pucci P; Bonotti A; Melaiu O; Cipollini M; Silvestri R; Vymetalkova V; Barone E; Paolicchi E; Corrado A; Lepori I; Dell'Anno I; Pellè L; Vodicka P; Mutti L; Foddis R; Cristaudo A; Gemignani F; Landi S
Occup Environ Med; 2017 Jun; 74(6):456-463. PubMed ID: 28343162
[TBL] [Abstract][Full Text] [Related]
23. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
[TBL] [Abstract][Full Text] [Related]
24. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Luo L; Shi HZ; Liang QL; Jiang J; Qin SM; Deng JM
Respir Med; 2010 Jan; 104(1):149-56. PubMed ID: 19945835
[TBL] [Abstract][Full Text] [Related]
26. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
[TBL] [Abstract][Full Text] [Related]
27. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.
Filiberti R; Marroni P; Spigno F; Merlo DF; Mortara V; Caruso P; Cioè A; Michelazzi L; Bruzzone A; Bobbio B; Simonassi C; Del Corso L; Galli R; Racchi O; Dini G; Linares R; Mencoboni M
Oncology; 2014; 86(1):33-43. PubMed ID: 24401539
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
[TBL] [Abstract][Full Text] [Related]
29. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
Park EK; Sandrini A; Yates DH; Creaney J; Robinson BW; Thomas PS; Johnson AR
Am J Respir Crit Care Med; 2008 Oct; 178(8):832-7. PubMed ID: 18583574
[TBL] [Abstract][Full Text] [Related]
30. Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population.
Park EK; Thomas PS; Creaney J; Johnson AR; Robinson BW; Yates DH
Clin Chem Lab Med; 2010 Jun; 48(6):869-74. PubMed ID: 20345230
[TBL] [Abstract][Full Text] [Related]
31. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
[TBL] [Abstract][Full Text] [Related]
32. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
33. Individual predictors of increased serum mesothelin in asbestos-exposed workers.
Filiberti R; Marroni P; Mencoboni M; Mortara V; Caruso P; Cioè A; Michelazzi L; Merlo DF; Bruzzone A; Bobbio B; Del Corso L; Galli R; Taveggia P; Dini G; Spigno F
Med Oncol; 2013 Mar; 30(1):422. PubMed ID: 23277285
[TBL] [Abstract][Full Text] [Related]
34. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.
Nelson HH; Almquist LM; LaRocca JL; Plaza SL; Lambert-Messerlian GM; Sugarbaker DJ; Bueno R; Godleski JJ; Marsit CJ; Christensen BC; Kelsey KT
Epigenetics; 2011 Aug; 6(8):1029-34. PubMed ID: 21775819
[TBL] [Abstract][Full Text] [Related]
35. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E
Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881
[TBL] [Abstract][Full Text] [Related]
36. Correlation of serum-soluble mesothelin-related protein, HMGB1 and CA125 in diffuse malignant peritoneal mesothelioma and their combined measurement for prognosis.
Wang L; Wang X; Sun N; Chen B
Scand J Clin Lab Invest; 2023 Apr; 83(2):74-78. PubMed ID: 36705231
[TBL] [Abstract][Full Text] [Related]
37. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
Katz SI; Roshkovan L; Berger I; Friedberg JS; Alley EW; Simone CB; Haas AR; Cengel KA; Sterman DH; Albelda SM
Lung Cancer; 2021 Apr; 154():5-12. PubMed ID: 33561782
[TBL] [Abstract][Full Text] [Related]
38. A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels.
Park EK; Wilson D; Yates DH
Clin Chem Lab Med; 2012 Dec; 50(12):2199-204. PubMed ID: 23093275
[TBL] [Abstract][Full Text] [Related]
39. Soluble mesothelin-related protein--a blood test for mesothelioma.
Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I
Lung Cancer; 2005 Jul; 49 Suppl 1():S109-11. PubMed ID: 15950789
[TBL] [Abstract][Full Text] [Related]
40. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.
Mundt F; Nilsonne G; Arslan S; Csürös K; Hillerdal G; Yildirim H; Metintas M; Dobra K; Hjerpe A
PLoS One; 2013; 8(8):e72030. PubMed ID: 23991032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]